Below is the abstract of a 2019 presentation by Amy Shapiro MD, CEO and co-medical director of the Indiana Hemophilia & Thrombosis Center in Indianapolis, Indiana, USA, describing the rebalancing agent concizumab, approved as Alhemo® by Health Canada in March 2023 but rejected by the US FDA on May 5, 2023, with a request for … Continue reading Concizumab, A “Rebalancing Agent”